Manitoba Adds 94 Additional Meds to Pharmacare Program

By Sarah Klein

WINNIPEG — The Manitoba government is adding new 94 drugs to be covered under the province’s pharmacare program starting next week.

Health Minister Sharon Blady says two of the medications will focus on people living with diabetes.

“When people are living with a chronic condition like diabetes, it can be a challenge to cover medication costs,” Blady said. “Adding these new drugs to the formulary will help Manitoba families address those costs and let them focus on other priorities as they receive the care they need.”

Two of the new drugs being added to the formulary are Komboglyze and Levemir, which are used for the treatment of diabetes.

Some of the other new drugs added to the formulary include:

  • Aubagio, for the treatment of multiple sclerosis;
  • Esbriet, for the treatment of idiopathic pulmonary fibrosis;
  • Galexos, for the treatment of Hepatitis C;
  • Invega Sustenna, for the treatment of schizophrenia;
  • Stivarga, for the treatment of gastrointestinal stromal tumors;
  • TOBI Podhaler, for the treatment of cystic fibrosis;
  • Actemra, for the treatment of polyarticular juvenile rheumatoid arthritis; and
  • a new strength of Xeomin, for the treatment of uncontrolled twitching of the neck and eye muscles.